Search

Your search keyword '"Kirova, Youlia"' showing total 1,057 results
Start Over Author "Kirova, Youlia"
1,057 results on '"Kirova, Youlia"'

7. Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Author

Rossi, Cédric, Manson, Guillaume, Marouf, Amira, Cabannes-Hamy, Aurélie, Nicolas-Virelizier, Emmanuelle, Maerevoet, Marie, Alcantara, Marion, Molina, Lysiane, Ceraulo, Antony, Poirée, Marilyne, Galtier, Jean, Diop, Nadia, Delette, Caroline, Segot, Amandine, Dubois, Sydney, Waultier, Agathe, Bernard, Sophie, Noël, Robin, Guidez, Stéphanie, Kohn, Milena, Bailly, Sébastien, Moatti, Hannah, Touati, Mohamed, Renaud, Loïc, Kanoun, Salim, Cottereau, Anne-Ségolène, Kirova, Youlia, Peignaux, Karine, Dourthe, Marie-Emilie, Simonin, Mathieu, Leblanc, Thierry, Quéro, Laurent, Krzisch, Daphné, Duléry, Remy, Grenier, Adrien, Gastinne, Thomas, Casasnovas, Olivier, Gallamini, Andrea, André, Marc, Morschhauser, Franck, Deau, Bénédicte, Fornecker, Luc-Mathieu, and Ghesquières, Hervé

Published
2024
Full Text
View/download PDF

10. Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group

Author

Elsayad, Khaled, Guenova, Emmanuella, Assaf, Chalid, Nicolay, Jan P., Trautinger, Franz, Stadler, Rudolf, Waldstein, Cora, Boterberg, Tom, Meijnders, Paul, Kirova, Youlia, Dobos, Gabor, Duque-Santana, Victor, Riggenbach, Elena, Elsheshtawy, Wael, Niezink, Anne, Papadavid, Evangelia, Scarisbrick, Julia, Vermeer, Maarten, Neelis, Karen J., Bagot, Martine, Battistella, Maxime, Quaglino, Pietro, Knobler, Robert, Kempf, Werner, Maklad, Ahmed, Adeberg, Sebastian, Kouloulias, Vassilis, Simontacchi, Gabriele, Corradini, Stefanie, König, Laila, Eich, Hans Theodor, Cowan, Richard, and Correia, Dora

Published
2024
Full Text
View/download PDF

13. A Short Reflection on Multidisciplinary Approaches to Women’s Health After Radiotherapy

Author

Barcellini, Amelia, Dominoni, Mattia, Biancuzzi, Helena, Dal Mas, Francesca, Venturini, Sara Carla, Muscettola, Giulia, Loap, Pierre, Kirova, Youlia, Gardella, Barbara, Orlandi, Ester, Marasca, Stefano, Series Editor, Fellegara, Anna Maria, Series Editor, Mussari, Riccardo, Series Editor, Adamo, Stefano, Editorial Board Member, Bartocci, Luca, Editorial Board Member, Caldarelli, Adele, Editorial Board Member, Campedelli, Bettina, Editorial Board Member, Castellano, Nicola, Editorial Board Member, Cepiku, Denita, Editorial Board Member, Cinquini, Lino, Editorial Board Member, Chiucchi, Maria Serena, Editorial Board Member, Dell'Atti, Vittorio, Editorial Board Member, De Luca, Francesco, Editorial Board Member, Fiorentino, Raffaele, Editorial Board Member, Giunta, Francesco, Editorial Board Member, Incollingo, Alberto, Editorial Board Member, Liberatore, Giovanni, Editorial Board Member, Lionzo, Andrea, Editorial Board Member, Lombardi, Rosa, Editorial Board Member, Maggi, Davide, Editorial Board Member, Mancini, Daniela, Editorial Board Member, Rossi, Francesca Manes, Editorial Board Member, Marchi, Luciano, Editorial Board Member, Mattei, Marco Maria, Editorial Board Member, Paolini, Antonella, Editorial Board Member, Paoloni, Mauro, Editorial Board Member, Paoloni, Paola, Editorial Board Member, Ruisi, Marcantonio, Editorial Board Member, Teodori, Claudio, Editorial Board Member, Terzani, Simone, Editorial Board Member, and Veltri, Stefania, Editorial Board Member

Published
2023
Full Text
View/download PDF

14. Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.

Author

Mutter, Robert, Choi, J, Jimenez, Rachel, Kirova, Youlia, Fagundes, Marcio, Haffty, Bruce, Amos, Richard, Bradley, Julie, Chen, Peter, Ding, Xuanfeng, Carr, Antoinette, Taylor, Leslie, Pankuch, Mark, Vega, Raymond, Ho, Alice, Nyström, Petra, McGee, Lisa, Urbanic, James, Cahlon, Oren, Maduro, John, and MacDonald, Shannon

Subjects
Breast, Breast Neoplasms, Consensus, Cost-Benefit Analysis, Female, Humans, Linear Energy Transfer, Neoplasm Recurrence, Local, Proton Therapy, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness
Abstract

Radiation therapy plays an important role in the multidisciplinary management of breast cancer. Recent years have seen improvements in breast cancer survival and a greater appreciation of potential long-term morbidity associated with the dose and volume of irradiated organs. Proton therapy reduces the dose to nontarget structures while optimizing target coverage. However, there remain additional financial costs associated with proton therapy, despite reductions over time, and studies have yet to demonstrate that protons improve upon the treatment outcomes achieved with photon radiation therapy. There remains considerable heterogeneity in proton patient selection and techniques, and the rapid technological advances in the field have the potential to affect evidence evaluation, given the long latency period for breast cancer radiation therapy recurrence and late effects. In this consensus statement, we assess the data available to the radiation oncology community of proton therapy for breast cancer, provide expert consensus recommendations on indications and technique, and highlight ongoing trials cost-effectiveness analyses and key areas for future research.

Published
2021

22. Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohort

Author

Ghannam, Youssef, Di Meglio, Antonio, Sarrade, Thomas, Jacquet, Alexandra, Everhard, Sibille, Kirova, Youlia, Peignaux, Karine, Guilbert, Philippe, Charra-Brunaud, Claire, Blanchecotte, Julien, Bochaton, Odile Fargier, Pasquier, David, Racadot, Séverine, Bourgier, Céline, Geffrelot, Julien, Benyoucef, Ahmed, Paris, François, Auzac, Guillaume, Luis, Inès Vaz, and Rivera, Sofia

Published
2022
Full Text
View/download PDF

30. Selection criteria for early breast cancer patients in the DBCG proton trial – The randomised phase III trial strategy

Author

Stick, Line Bjerregaard, Lorenzen, Ebbe Laugaard, Yates, Esben Svitzer, Anandadas, Carmel, Andersen, Karen, Aristei, Cynthia, Byrne, Orla, Hol, Sandra, Jensen, Ingelise, Kirby, Anna M., Kirova, Youlia M., Marrazzo, Livia, Matías-Pérez, Angela, Nielsen, Mette Marie Bruun, Nissen, Henrik Dahl, Oliveros, Sileida, Verhoeven, Karolien, Vikström, Johan, and Offersen, Birgitte Vrou

Published
2021
Full Text
View/download PDF

38. Practice-changing trials on breast cancer.

Author

Kirova, Youlia, Bouziane, Jihane, and Loap, Pierre

Subjects
*BREAST cancer treatment, *CANCER radiotherapy, *DOSE fractionation, *MASTECTOMY, *DATA analysis
Abstract

There is new data in the fractionation modalities and these are the really the practice-changing trials of last years: can we use hypo fractionated whole breast radiotherapy in patients presented with ductal carcinoma in situ? Can we realize hypofractionated whole breast radiotherapy with simultaneous integrated boost? What about hypofractionated irradiation after mastectomy with reconstruction? Can we do hypofractionation to lymph nodes without risk of increased toxicity? The purpose of this work is to respond with the last evidence-based recently presented or published data. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer

Author

Kaidar-Person, Orit, Vrou Offersen, Birgitte, Hol, Sandra, Arenas, Meritxell, Aristei, Cynthia, Bourgier, Celine, Cardoso, Maria Joao, Chua, Boon, Coles, Charlotte E., Engberg Damsgaard, Tine, Gabrys, Dorota, Jagsi, Reshma, Jimenez, Rachel, Kirby, Anna M., Kirkove, Carine, Kirova, Youlia, Kouloulias, Vassilis, Marinko, Tanja, Meattini, Icro, Mjaaland, Ingvil, Nader Marta, Gustavo, Witt Nystrom, Petra, Senkus, Elzbieta, Skyttä, Tanja, Tvedskov, Tove F., Verhoeven, Karolien, and Poortmans, Philip

Published
2019
Full Text
View/download PDF

44. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG

Author

Binkley, Michael S., Brady, Jessica L., Hajj, Carla, Chelius, Monica, Chau, Karen, Balogh, Alex, Levis, Mario, Filippi, Andrea Riccardo, Jones, Michael, Ahmed, Sameera, MacManus, Michael, Wirth, Andrew, Oguchi, Masahiko, Vistisen, Anders Krog, Andraos, Therese Youssef, Ng, Andrea K., Aleman, Berthe M.P., Choi, Seo Hee, Kirova, Youlia M., Hardy, Sara, Reinartz, Gabriele, Eich, Hans T., Bratman, Scott V., Constine, Louis S., Suh, Chang-Ok, Dabaja, Bouthaina, El-Galaly, Tarec C., Hodgson, David C., Ricardi, Umberto, Yahalom, Joachim, Mikhaeel, N. George, and Hoppe, Richard T.

Published
2019
Full Text
View/download PDF

49. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG

Author

Brady, Jessica L., Binkley, Michael S., Hajj, Carla, Chelius, Monica, Chau, Karen, Balogh, Alex, Levis, Mario, Filippi, Andrea Riccardo, Jones, Michael, Mac Manus, Michael, Wirth, Andrew, Oguchi, Masahiko, Vistisen, Anders Krog, Andraos, Therese Youssef, Ng, Andrea K., Aleman, Berthe M.P., Choi, Seo Hee, Kirova, Youlia, Hardy, Sara, Reinartz, Gabriele, Eich, Hans T., Bratman, Scott V., Constine, Louis S., Suh, Chang-Ok, Dabaja, Bouthaina, El-Galaly, Tarec C., Hodgson, David C., Ricardi, Umberto, Yahalom, Joachim, Hoppe, Richard T., and Mikhaeel, N. George

Published
2019
Full Text
View/download PDF

50. Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia–Telangiectasia Mutated Variant Carriers.

Author

Bensenane, Rayan, Beddok, Arnaud, Lesueur, Fabienne, Fourquet, Alain, Warcoin, Mathilde, Le Mentec, Marine, Cavaciuti, Eve, Le Gal, Dorothée, Eon-Marchais, Séverine, Andrieu, Nadine, Stoppa-Lyonnet, Dominique, and Kirova, Youlia

Subjects
RISK assessment, STATISTICAL models, LYMPHEDEMA, THERAPEUTIC complications, RADIOTHERAPY, RESEARCH funding, SKIN inflammation, BREAST tumors, GENETIC markers, SCIENTIFIC observation, FISHER exact test, ATAXIA telangiectasia, CANCER patients, RETROSPECTIVE studies, RADIATION dosimetry, DESCRIPTIVE statistics, CHI-squared test, FIBROSIS, KAPLAN-Meier estimator, ESTROGEN receptors, FLUORESCENCE in situ hybridization, GENETIC mutation, RADIATION doses, DATA analysis software, ALLELES, GENOTYPES, SINGLE nucleotide polymorphisms, SEQUENCE analysis, EPIDERMAL growth factor receptors, DEGLUTITION disorders
Abstract

Simple Summary: Of the worldwide population, 0.5 to 1% of people are carrying a heterozygous mutation of Ataxia–Telangiectasia Mutated (ATM) gene. While the clinical radiosensitivity of carriers of germline biallelic inactivation of the ATM gene is well described, controversies are observed for monoallelic carriers of ATM mutation. The aim of this study is to evaluate acute and late toxicities after adjuvant breast radiation therapy in ATM pathogenic variant carriers. This observational retrospective study showed an absence of significative acute and late toxicities after breast radiation therapy among patients carrying a heterozygous rare variant of the ATM gene. Single nucleotide polymorphism rs1801516 (G/A), described as associated with late subcutaneous fibrosis, was not associated with this late adverse event in our study. The Ataxia–Telangiectasia Mutated (ATM) gene is implicated in DNA double-strand break repair. Controversies in clinical radiosensitivity remain known for monoallelic carriers of the ATM pathogenic variant (PV). An evaluation of the single-nucleotide polymorphism (SNP) rs1801516 (G-A) showed different results regarding late subcutaneous fibrosis after breast radiation therapy (RT). The main objective of this study was to evaluate acute and late toxicities in carriers of a rare ATM PV or predicted PV and in carriers of minor allele A of rs1801516 facing breast RT. Fifty women with localized breast cancer treated with adjuvant RT between 2000 and 2014 at Institut Curie were selected. Acute and late toxicities in carriers of a rare PV or predicted PV (n= 9), in noncarriers (n = 41) and in carriers of SNP rs1801516 (G-A) (n = 8), were examined. The median age at diagnosis was 53 years old and 82% of patients had an invasive ductal carcinoma and 84% were at clinical stage I–IIB. With a median follow-up of 13 years, no significant difference between carriers and noncarriers was found for acute toxicities (p > 0.05). The same results were observed for late toxicities without an effect from the rs1801516 genotype on toxicities. No significant difference in acute or late toxicities was observed between rare ATM variant carriers and noncarriers after breast RT for localized breast cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results